ActoGeniX: 20 million euros round


Ghent – The Belgian biopharma start-up ActoGeniX has closed a series A financing round in the volume of a20 million. The transaction was co-led by the two renowned VC investors Life Sciences Partners and GIMV. ActoGeniX has already announced a first closing of this transaction, raising a11.5 million. The company, which was founded in summer 2006, is developing a portfolio of novel therapeutic products addressing major diseases with unmet medical need, including gastrointestinal diseases, auto-immunity, allergy and metabolic diseases. ActoGeniX’ initial focus is on inflammatory bowel diseases and its lead product AG011 has been successfully tested in a clinical trial with Crohn’s disease patients. The company’s technology provides a solution to deliver active biologicals locally in the gastrointestinal tract, leading to a direct effect on target receptors present in the gut.



Leiden – Overshadowed by contamination problems at Crucell N.V.’s vaccine plant in South Korea, pharmaceutical and healthcare giant Johnson & Johnson has continued the purchase of 82.5 % of the Dutch biotechnology vaccine maker...



Leuven – Researchers from Leuven University have demonstrated that German Merck’s monoclonal EGF receptor (EGFR) antagonist cetuximab (Erbitux) offers benefits to patients with metastatic colorectal cancer even when they carry...



Brussels - Healthcare institutions from Europe have launched a new pilotprocess testing multi-stakeholder consultations in early-stage drugdevelopment. The purpose of the project is to reach an agreement about whatconstitutes a...



Leiden/New Brunswick – Johnson & Johnson will acquire all outstanding shares of Dutch Crucell N.V. for approximately EUR1.75 billion in a recommended cash tender offer, according to the companies. J&J said that it expects to...



Leiden/News Brunswick - Johnson & Johnson is set to bag all outstanding shares of Dutch protein and vaccine developer Crucell N.V. Currently Johnson & Johnson, through an affiliate, holds approx. 17.9% of the shares of Crucell...



Rotterdam/Leuven – Cartilage replacement specialist TiGenix N.V. has entered into an agreement with its academic partners KU Leuven and Ghent University, the Dutch company Therosteon and a consortium of investors for the...



Groningen – Researchers from the University of Groningen have identified a new mechanism that enables cancer cells to resist platinum-based chemotherapy. In resistant cancer stem cells of patients with testicular cancer, the team...

Displaying results 71 to 80 out of 304

< Previous 71-80 Next >

© 2007-2014 BIOCOM

Product of the week



All Events

Current issue

All issues